Abstract
Myocardial perfusion imaging with 201 Tl chloride suffers from a number of physical, geometric, and dosimetric constraints that could be diminished if an agent labeled with 99mTc were available. The cationic complex 99mTc hexakis-(t-butylisonitrile)technetium(I) ([99mTc]TBI) has been shown to concentrate in the myocardial tissue of both animals and humans, with preliminary clinical studies demonstrating a number of technical attributes not possible with 201 Tl. Technetium-99m-TBI is a promising myocardial imaging agent that may permit high quality planar, gated, and tomographic imaging of both myocardial ischemia and infarction with reduced imaging times and improved resolution.
